Strategies for designing vaccines eliciting Th1 responses in humans.
There is currently a major interest in designing vaccines capable of eliciting strong cellular immune responses. The induction of cytotoxic and Th1 helper cellular responses is for example highly desirable for vaccines targeting either chronic infectious diseases or cancers (therapeutic vaccines). Similarly, Th1 vaccines would be useful in redirecting inappropriate antigen-specific immune responses in patients with autoimmune diseases and allergies. Importantly, emerging technologies and a better understanding of the physiology of immune responses offer new avenues to rationally design such vaccines. Approaches based on the identification and selection of immunogens containing T cell epitopes can be used, together with epitope-enhancement strategies, to increase binding to MHC, or to improve recognition by T cell receptor complexes. Optimized immunogens can subsequently be presented to the immune system with appropriate vectors allowing to target professional antigen-presenting cells, such as dendritic cells. Such antigen presentation platforms can be used alone or in association, as part of mixed immunization regimens (heterologous prime-boosts), in order to elicit broad immune responses. The rational design of Th1 adjuvants can also benefit from our better understanding of the nature of proinflammatory signals leading to the initiation of both innate and adaptive immune effector mechanisms. Candidate Th1 vaccines (or components such as vectors or adjuvants) will have to be tested in exploratory clinical studies, implying a need for new assays and methods allowing to assess in a qualitative and quantitative manner low-frequency T cell responses in humans.
Research and Development, Aventis Pasteur, Campus Mérieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France. philippe.moingeon@aventis.com
P
P
Moingeon
D000937:Antigen-Antibody Reactions / Q000235:genetics / Q000502:physiology; D000941:Antigens / Q000235:genetics / Q000276:immunology; D019496:Cancer Vaccines / Q000235:genetics; D015195:Drug Design; D018984:Epitopes, T-Lymphocyte / Q000235:genetics* / Q000276:immunology*; D005786:Gene Expression Regulation; D005818:Genetic Engineering / Q000379:methods / Q000639:trends; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D018417:Th1 Cells / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000235:genetics*
D000941:Antigens; D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D014614:Vaccines, Synthetic